Remove Cardiology Remove Clinical Trials Remove Containment Remove Research
article thumbnail

Cardiol Therapeutics Announces Formation of Data Safety Monitoring and Clinical Endpoint Committees for Phase II/III Outcomes Trial in High-Risk Patients Hospitalized with COVID-19

The Pharma Data

Dr. Rouleau has an international reputation in cardiovascular research, particularly in the field of both basic mechanisms and improving the clinical care of patients with heart failure. He has been an Investigator in over 240 research projects with research funding exceeding $120 million.

Trials 52
article thumbnail

MolecuLight’s CEO Anil Amlani Discusses Next Steps for Their Wound Imaging Devices

XTalks

The Toronto-based company has recently announced positive results from an independent clinical trial which showed that their fluorescence imaging device MolecuLight i :X improved 12-week wound healing of diabetic foot ulcers by 204 percent. What clinical value does this expanded clearance provide? When was the company founded?

Bacteria 111
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Caelum and Alexion Announce Upcoming Data Presentations at the 62nd American Society of Hematology Annual Meeting and Exposition

The Pharma Data

Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. This press release and further information about Alexion can be found at: www.alexion.com.

article thumbnail

Novartis Entresto receives positive CHMP opinion for pediatric heart failure

The Pharma Data

FortiHFy includes trials across the spectrum of HF, such as PARADIGM-HF, PIONEER-HF, PANORAMA-HF, TRANSITION, PROVE-HF, PARAGON-HF and PARAMOUNT. Entresto contains the neprilysin inhibitor sacubitril and the angiotensin receptor blocker (ARB) valsartan 4,5. Source link: [link]

article thumbnail

Novartis Leqvio®* (inclisiran) analyses show effective and sustained LDL-C reduction.

The Pharma Data

Results were presented at the ESC Congress 2021, organized by the European Society of Cardiology (ESC). In three clinical trials, patients taking Leqvio maintained LDL-C reduction throughout each six-month dosing interval 8,10. In the first analysis, patients with established CeVD treated with Leqvio achieved an average 55.2%

RNA 52
article thumbnail

Novartis new analysis shows high consistency in lowering LDL-C in individual response with investigational inclisiran

The Pharma Data

Presented at the ESC Congress 2020, the annual meeting of the European Society of Cardiology, the analysis evaluated the efficacy and tolerability of inclisiran on top of a maximally tolerated dose of statins, in two studies of more than 2,300 patients (of which 1,164 were on inclisiran) from the Phase III trials.

article thumbnail

Alexion Highlights Commercial, Clinical and Financial Progress at the 39th Annual J.P. Morgan Healthcare Conference

The Pharma Data

Dosing is underway in Phase 3 trials of ULTOMIRIS in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), ALXN2060 (AG10) in ATTR cardiomyopathy in Japan , CAEL -101 in AL amyloidosis and ALXN2040 in paroxysmal nocturnal hemoglobinuria (PNH) patients with extravascular hemolysis (EVH).